Impact of serum albumin levels on long-term all-cause, cardiovascular, and cardiac mortality in patients with first-onset acute myocardial infarction

Xia, Ming; Zhang, Chi; Gu, Jun; Chen, Jing; Wang, Linchi; Lu, Yan; Huang, Chunyan; He, Yao; Yang, Xiangjun

doi:10.1016/j.cca.2017.12.014

Cited by 41 publications

(36 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During full-text assessment, 14 articles were further removed for various reasons. Finally, eight studies [6][7][8][9][10][11][12][13] were included in the meta-analysis ( Figure 1). Table 1 summarizes the main characteristics of eligible studies.…”

Section: Search Results and Study Characteristicsmentioning

confidence: 99%

“…Table 1 summarizes the main characteristics of eligible studies. These studies were published from 2006 to 2018 and conducted in China [6,12,13], Turkey [7,9], Israel [10], Japan [8], and Mexico [11]. The sample size of each study ranged from 62 to 8750, with a total of 21667 ACS patients.…”

Section: Search Results and Study Characteristicsmentioning

confidence: 99%

“…The sample size of each study ranged from 62 to 8750, with a total of 21667 ACS patients. Three studies [8,9,13] were consecutive designs and others were retrospective studies. The duration of follow-up was up to 6.1 years.…”

Section: Search Results and Study Characteristicsmentioning

confidence: 99%

“…Low serum albumin level has been identified as a risk factor for the development of coronary artery disease [5]. Several epidemiological studies [6][7][8][9][10][11][12][13] have examined the association between serum albumin and adverse outcomes in ACS patients. However, these available studies differed from study design, population studied, sample size, cut-off level of low serum albumin, and adjustment for covariates.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Serum albumin level for prediction of all-cause mortality in acute coronary syndrome patients: a meta-analysis

2020

View full text Add to dashboard Cite

The prognostic utility of serum albumin level as a predictor of survival in patients with acute coronary syndrome (ACS) has attracted considerable attention. This meta-analysis sought to investigate the prognostic value of serum albumin level for predicting all-cause mortality in ACS patients. A systematic literature search was conducted in Pubmed and Embase databases until 5 March 2019. Epidemiological studies investigating the association between serum albumin level and all-cause mortality risk in ACS patients were included. Eight studies comprising 21667 ACS patients were included. Meta-analysis indicated that ACS patients with low serum albumin level had an increased risk of all-cause mortality (risk ratio [RR] 2.15; 95% confidence interval [CI] 1.68–2.75) after adjusting for important covariates. Subgroup analysis showed that the impact of low serum albumin level was stronger in hospital mortality (RR 3.09; 95% CI 1.70–5.61) than long-term all-cause mortality (RR 1.75; 95% CI 1.54–1.98). This meta-analysis demonstrates that low serum albumin level is a powerful predictor of all-cause mortality in ACS patients, even after adjusting usual confounding factors. However, there is lack of clinical trials to demonstrate that correcting serum albumin level by means of intravenous infusion reduces the excess risk of death in ACS patients.

show abstract

Section: Search Results and Study Characteristicsmentioning

confidence: 99%

Section: Search Results and Study Characteristicsmentioning

confidence: 99%

Section: Search Results and Study Characteristicsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Serum albumin level for prediction of all-cause mortality in acute coronary syndrome patients: a meta-analysis

2020

View full text Add to dashboard Cite

show abstract

“…Previous studies demonstrated that serum albumin levels are closely associated with the occurrence, development and severity of coronary heart disease (26). Recent studies also reported that decreased concentration of albumin is a risk factor for incident acute MI in patients with CAD and is related to elevated cardiovascular morbidity and long-term outcomes (27). Furthermore, hypoalbuminemia can predict the occurrence of the no-flow phenomenon in patients with STEMI after PCI (28).…”

Section: Discussionmentioning

confidence: 99%

Relationship between fibrinogen -to- albumin ratio and angiographic no-reflow in elderly patients with st-elevation myocardial infarction treated with primary percutaneous coronary intervention

Ekizler¹,

Tak²,

Çay³

2019

tjgeri

View full text Add to dashboard Cite

Introduction: Primary percutaneous coronary intervention carries a low success rate and high procedural risk in elderly patients. No-reflow is a serious complication of primary percutaneous coronary intervention in the treatment of acute ST-elevation myocardial infarction. We evaluated whether admission fibrinogen-to-albumin ratio, which has emerged as an inflammatory and haemorheological marker for predicting adverse outcomes in some cardiovascular diseases, predicts angiographic no-reflow in elderly patients with ST-elevation myocardial infarction.Materials and Method: In total, 617 patients (78.1% men; median age, 75 (68-80years) who underwent primary percutaneous coronary intervention and were admitted within 12 hours from the onset of symptoms were classified into two groups based on the final thrombolysis in myocardial infarction flow grading. Noreflow was defined as post-percutaneous coronary intervention thrombolysis in myocardial infarction grade 0, 1 and 2, and angiographic success (normal reflow) was defined as thrombolysis in myocardial infarction grade 3.Results: Of the total, 29 (51.8%) patients were found to be frail, 22 (39.3%) were found to be prefrail, and 5 (8.9%) were found be nonfrail. Further, 34 (60.8%) patients were at the risk of malnutrition. Additionally, 38 (67.8%) patients had delirium and 8 (14%) patients died during the postoperative month 1. Although Nutritional Risk Screening 2002 scores positively correlated with first-month mortality, no correlation was found between malnutrition and delirium status. A positive correlation was found between clinical frailty scale score and delirium; however, there was no correlation between clinical frailty scale score and firstmonth mortality. Positive predictive values of malnutrition and frailty together for first-month mortality increased up to 54.5% from 17.6% and 13.6 and that of delirium increased to 80.2% from 54.5% and 72.4%, respectively.Conclusion: The incidence of angiographic no-reflow was 19.9% (n = 123). Patients with no-reflow had higher rates of diabetes and smoking, higher thrombus burden and Killip class≥2 on admission and lower baseline left ventricular ejection fraction; they also had increased white blood cell counts, C-reactive protein and fibrinogen-to-albumin ratio levels at admission than the normal flow group. In multivariate analysis, white blood cell count, smoking and fibrinogen-to-albumin ratio were independent predictors of angiographic no-reflow. ABSTRACTGiriş: Genç hastalarla karşılaştırıldığında, ileri yaş hastalarda primer perkütan koroner girişim, daha düşük başarı ve artmış prosedürel komplikasyonlarla ilişkilidir. No-reflow fenomeni, ST-yükselmeli miyokard enfarktüsü ile primer perkütan koroner girişim yapılan hastalarda karşılaşılabilecek en ciddi komplikasyonlardan biridir. Fibrinojen / albümin oranı; bazı kardiyovasküler hastalıklarda istenmeyen sonlanımları öngördüren, inflamasyon ve hemoreolojiyi yansıtan bir parametre olarak ortaya çıkmıştır. Biz bu çalışmada ST-yükselmeli miyokard enfarktüsü ile başv...

show abstract

Prognostic impact of follow‐up serum albumin after acute myocardial infarction

Yoshioka

Tanaka

Nishihira³

et al. 2021

ESC Heart Failure

View full text Add to dashboard Cite

Aims Previous studies have suggested that low serum albumin (LSA) at admission for acute myocardial infarction (AMI) is associated with adverse in-hospital outcomes. The aim of this study was to investigate whether LSA in the remote phase after AMI is prognostic for long-term outcomes. Methods and resultsThis was a single-centre, retrospective study of consecutive patients admitted for AMI from 2008 to 2016. Serum albumin concentrations were measured serially at admission and 1 year after discharge in Japanese patients. Occurrence of a composite of hospitalization for heart failure and cardiovascular death was the primary endpoint. The prognostic impact of remote LSA, defined as a serum albumin level < 3.8 g/dL at 1 year after discharge, was investigated with a multivariate-adjusted Cox model. Among 1424 subjects analysed, 289 (20.3%) had LSA at admission, and 165 (11.6%) had LSA at 1 year after discharge. During follow-up (median: 4.1 years), the primary endpoint occurred in 31/165 (18.8%) patients with remote LSA and 42/1259 (3.3%) patients without it [adjusted hazard ratio (aHR), 2.76; 95% confidence interval (CI), 1.32 to 5.72; P = 0.007]. The all-cause death rate was 29.7% (49/165) in patients with remote LSA and 4.3% (54/1259) in patients without it (aHR, 4.02; 95% CI, 2.36 to 6.87; P < 0.001). The prognostic impact of remote LSA was consistent across albumin status in the acute phase of AMI. Conclusions Regardless of albumin status in the acute phase of AMI, LSA in the remote phase after AMI was significantly associated with long-term adverse outcomes.

show abstract

Impact of serum albumin levels on long-term all-cause, cardiovascular, and cardiac mortality in patients with first-onset acute myocardial infarction

Cited by 41 publications

References 36 publications

Serum albumin level for prediction of all-cause mortality in acute coronary syndrome patients: a meta-analysis

Serum albumin level for prediction of all-cause mortality in acute coronary syndrome patients: a meta-analysis

Relationship between fibrinogen -to- albumin ratio and angiographic no-reflow in elderly patients with st-elevation myocardial infarction treated with primary percutaneous coronary intervention

Prognostic impact of follow‐up serum albumin after acute myocardial infarction

Contact Info

Product

Resources

About